SMAD2 and hepatocellular carcinoma: In summary, this study provides evidence that PAK3 is an oncogene in HCC and contributes to EMT in HCC by regulating Smad2 and Smad3, suggesting that PAK3 might be a potential biomarker and attractive therapeutic target for HCC.